The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal
Open accessAbstract
BACKGROUND: The risk of premature cardiovascular disease in patients with familial hypercholesterolemia (FH) can be profoundly reduced by cholesterol-lowering therapy, and current guidelines for FH advocate ambitious low-density lipoprotein cholesterol (LDL-C) goals. In the present study, we determined whether these goals are reflected in current clinical practice once FH has been diagnosed. METHODOLOGY/PRINCIPAL FINDINGS: In 2008, we sent questionnaires to all subjects (aged 18-65 years) who were molecularly diagnosed with FH in the year 2006 through the screening program in The Netherlands. Of these 1062 subjects, 781 completed the questionnaire (46% males; mean age: 42+/-12 years; mean LDL-C at molecular diagnosis (baseline): 4.1+/-1.3 mmol/L). The number of persons that used cholesterol-lowering therapy increased from 397 (51%) at baseline to 636 (81%) after diagnosis. Mean treated LDL-C levels decreased significantly to 3.2+/-1.1 mmol/L two years after diagnosis. Only 22% achieved the LDL-C target level of < or = 2.5 mmol/L. CONCLUSIONS/SIGNIFICANCE: The proportion of patients using cholesterol-lowering medication was significantly increased after FH diagnosis through genetic cascade screening. The attained LDL-C levels were lower than those reported in previous surveys on medication use in FH, which could reflect the effect of more stringent lipid target levels. However, only a minority of the medication users reached the LDL-C target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In some conditions the process of genetic counselling can be optimized and extended with cascade screening, which identifies patients at risk and enables timely treatment of affected relatives, as is the case for familial hypercholesterolaemia.72,75”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800742 · Cited by 1,241 · cited 1×
“20 based on the approximately 17% additional LDL-C lowering when added to statins.[14] The potency of a resin was estimated as 1.”
BackgroundSelf-citationSmilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationEfficacy of statins in familial hypercholesterolaemia: a long term cohort study
Versmissen, J., Oosterveer, D. M., Yazdanpanah, M., Defesche, J. C., Basart, D. C. G., Liem, A. H., Heeringa, J., Witteman, J. C., Lansberg, P. J., Kastelein, J. J. P., et al. (2008) · BMJ · doi:10.1136/bmj.a2423 · Cited by 721
Self-citationRISKS OF ISCHÆMIC HEART-DISEASE IN FAMILIAL HYPERLIPOPROTEINÆMIC STATES
Slack, J. (1969) · The Lancet · doi:10.1016/s0140-6736(69)90930-1 · Cited by 623
Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands
Umans-Eckenhausen, M. A., Defesche, J. C., Sijbrands, E. J., Scheerder, R. L., & Kastelein, J. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03587-x · Cited by 489
Self-citationPleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?
Robinson, J. G., Smith, B., Maheshwari, N., & Schrott, H. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.05.085 · Cited by 407
Pijlman, A. H., Huijgen, R., Verhagen, S. N., Imholz, B. P. M., Liem, A. H., Kastelein, J. J. P., Abbink, E. J., Stalenhoef, A. F. H., & Visseren, F. L. J. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.09.014 · Cited by 238
Self-citation
Cited by
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Authors/Task Force Members, Graham, I., Atar, D., Borch-Johnsen, K., Boysen, G., Burell, G., Cifkova, R., Dallongeville, J., De Backer, G., Ebrahim, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,753
Authors/Task Force Members, Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., et al. (2016) · European Journal of Preventive Cardiology · doi:10.1177/2047487316653709 · Cited by 1,334
Authors/Task Force Members: Joep Perk (Chairperson) (Sweden)*, G. D. B. (. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312450228 · Cited by 863
Gidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.007 · Cited by 691
Kastelein, J. J. P., Ginsberg, H. N., Langslet, G., Hovingh, G. K., Ceska, R., Dufour, R., Blom, D., Civeira, F., Krempf, M., Lorenzato, C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv370 · Cited by 533
Self-citationPerk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 311
Community, R. O. T. G. F. H., Wilemon, K. A., Patel, J., Aguilar-Salinas, C., Ahmed, C. D., Alkhnifsawi, M., Almahmeed, W., Alonso, R., Al-Rasadi, K., Badimon, L., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2019.5173 · Cited by 256
Self-citationDiagnosis and treatment of familial hypercholesterolaemia
Hovingh, G. K., Davidson, M. H., Kastelein, J. J. P., & O'Connor, A. M. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht015 · Cited by 256
Self-citationVallejo-Vaz, A. J., De Marco, M., Stevens, C. A. T., Akram, A., Freiberger, T., Hovingh, G. K., Kastelein, J. J. P., Mata, P., Raal, F. J., Santos, R. D., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.051 · Cited by 231
Self-citationGinsberg, H. N., Rader, D. J., Raal, F. J., Guyton, J. R., Baccara-Dinet, M. T., Lorenzato, C., Pordy, R., & Stroes, E. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6685-y · Cited by 214
Familial hypercholesterolaemia: A model of care for Australasia
Watts, G. F., Sullivan, D. R., Poplawski, N., van Bockxmeer, F., Hamilton-Craig, I., Clifton, P. M., O’Brien, R., Bishop, W., George, P., Barter, P. J., et al. (2011) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2011.06.001 · Cited by 204
Sjouke, B., Langslet, G., Češka, R., Nicholls, S. J., Nissen, S. E., Öhlander, M., Ladenson, P. W., OLSSON, A. G., Hovingh, G. K., & Kastelein, J. J. P. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70006-3 · Cited by 151
Self-citationGenetics and Genomics for the Prevention and Treatment of Cardiovascular Disease: Update
Ganesh, S. K., Arnett, D. K., Assimes, T. L., Basson, C. T., Chakravarti, A., Ellinor, P. T., Engler, M. B., Goldmuntz, E., Herrington, D. M., Hershberger, R. E., et al. (2013) · Circulation · doi:10.1161/01.cir.0000437913.98912.1d · Cited by 145
Kastelein, J. J. P., Robinson, J. G., Farnier, M., Krempf, M., Langslet, G., Lorenzato, C., Gipe, D. A., & Baccara‐Dinet, M. T. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6523-z · Cited by 114
Self-citationMotazacker, M. M., Pirruccello, J. P., Huijgen, R., Do, R., Gabriel, S., Peter, J., Kuivenhoven, J. A., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs010 · Cited by 101
Self-citationCascade screening for familial hypercholesterolemia: Practical consequences
Louter, L., Defesche, J. C., & van Lennep, J. E. R. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.019 · Cited by 95
Hypercholesterolemia: The role of PCSK9
Melendez, Q. M., Krishnaji, S. T., Wooten, C. J., & Lopez, D. (2017) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2017.06.001 · Cited by 101
Cascade Screening for Familial Hypercholesterolemia (FH)
Ned, R. M., & Sijbrands, E. J. G. (2011) · PLoS Currents · doi:10.1371/currents.rrn1238 · Cited by 96
Self-citationHuijgen, R., Hutten, B. A., Kindt, I., Vissers, M. N., & Kastelein, J. J. P. (2012) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.111.962456 · Cited by 74
Self-citationBell, D. A., Pang, J., Burrows, S., Bates, T. R., BOCKXMEER, F. M. V., Hooper, A. J., O'Leary, P. C., Burnett, J. R., & Watts, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.12.036 · Cited by 81
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)
Averna, M., Cefalu, A. B., Casula, M., Noto, D., Arca, M., Bertolini, S., Calandra, S., Catapano, A. L., Tarugi, P., Arca, M., et al. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.07.001 · Cited by 73
Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
Huijgen, R., Fouchier, S. W., Denoun, M., Hutten, B. A., Vissers, M. N., Lambert, G., & Kastelein, J. J. P. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p023994 · Cited by 67
Self-citationKastelein, J. J. P., Hovingh, G. K., Langslet, G., Baccara-Dinet, M. T., Gipe, D. A., Chaudhari, U., Zhao, J., Minini, P., & Farnier, M. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.12.004 · Cited by 67
Self-citationMinno, A. D., Lupoli, R., Calcaterra, I. L., Poggio, P., Forte, F., Spadarella, G., Ambrosino, P., Iannuzzo, G., & Minno, M. N. D. D. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016262 · Cited by 73
Identification of people with heterozygous familial hypercholesterolemia
Haase, A., & Goldberg, A. C. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283556c33 · Cited by 63
Evolocumab (AMG 145) for primary hypercholesterolemia
Langslet, G., Emery, M. G., & Wasserman, S. M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1030395 · Cited by 65
Braamskamp, M. J. A. M., Kusters, D. M., Avis, H. J., Smets, E. M. A., Wijburg, F. A., Kastelein, J. J. P., Wiegman, A., & Hutten, B. A. (2015) · Pediatric Drugs · doi:10.1007/s40272-014-0116-y · Cited by 64
Self-citationRidker, P. M., Rose, L. M., Kastelein, J. J. P., Santos, R. D., Wei, C., Revkin, J. H., Yunis, C., Tardif, J., & Shear, C. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.03.088 · Cited by 63
Self-citationHuman Pluripotent Stem Cells for Modelling Human Liver Diseases and Cell Therapy
Dianat, N., Steichen, C., Vallier, L., Weber, A., & Dubart‐Kupperschmitt, A. (2013) · Current Gene Therapy · doi:10.2174/1566523211313020006 · Cited by 67
Farnier, M., Hovingh, G. K., Langslet, G., Dufour, R., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Guyton, J. R. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.036 · Cited by 62
Béliard, S., Carreau, V., Carrié, A., Giral, P., Duchêne, E., Farnier, M., Ferrières, J., Fredenrich, A., Krempf, M., Luc, G., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.02.021 · Cited by 59
Alonso, R., de Isla, L. P., Muñiz-Grijalvo, O., & Mata, P. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s192401 · Cited by 67
Bogsrud, M. P., Græsdal, A., Johansen, D., Langslet, G., Hovland, A., Arnesen, K.-E., Mundal, L. J., Retterstøl, K., Wium, C., & Holven, K. B. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.010 · Cited by 53
Huijgen, R., Sjouke, B., Vis, K., de Randamie, J. S. E., Defesche, J. C., Kastelein, J. J. P., Hovingh, G. K., & Fouchier, S. W. (2011) · Human Mutation · doi:10.1002/humu.21660 · Cited by 47
Self-citationZannad, F. M., Backer, G. D., Graham, I. M., Lorenz, M., Mancia, G., Morrow, D. A., Reiner, Ž., Köenig, W., Dallongeville, J., MacFadyen, R. J., et al. (2012) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.01023.x · Cited by 48
Ademi, Z., Norman, R., Pang, J., Sijbrands, E. J. G., Watts, G. F., Hutten, B. A., & Wiegman, A. (2023) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2023.0763 · Cited by 49
Self-citationHuijgen, R., Kindt, I., Fouchier, S. W., Defesche, J. C., Hutten, B. A., Kastelein, J. J. P., & Vissers, M. N. (2010) · Human Mutation · doi:10.1002/humu.21258 · Cited by 45
Self-citationLee, S., Akioyamen, L. E., Aljenedil, S., Rivière, J., Ruel, I. L., & Genest, J. J. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319829746 · Cited by 47
Kusters, D. M., Huijgen, R., Defesche, J. C., Vissers, M. N., Kindt, I., Hutten, B. A., & Kastelein, J. J. P. (2011) · Netherlands Heart Journal · doi:10.1007/s12471-011-0076-6 · Cited by 46
Self-citationLoaiza, N., Hartgers, M. L., Reeskamp, L. F., Balder, J.-W., Rimbert, A., Bazioti, V., Wolters, J. C., Winkelmeijer, M., Jansen, H., Dallinga‐Thie, G. M., et al. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.313470 · Cited by 50
Huijgen, R., Vissers, M. N., Kindt, I., Trip, M. D., de Groot, E., Kastelein, J. J. P., & Hutten, B. A. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.959239 · Cited by 42
Self-citationRallidis, L. S., Triantafyllis, A. S., Tsirebolos, G., Katsaras, D. N., Rallidi, M., Moutsatsou, P., & Lekakis, J. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.03.023 · Cited by 44
Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study
Gaudet, D., Lopez-Sendon, J. L., Averna, M. R., Bigot, G., Banach, M., Letierce, A., Loy, M., Samuel, R., Manvelian, G. Z., Batsu, I., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa097 · Cited by 42
Besseling, J., Sjouke, B., & Kastelein, J. J. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.011 · Cited by 47
Self-citationPatient acceptance of genetic testing for familial hypercholesterolemia in the CASCADE FH Registry
Gidding, S. S., Sheldon, A., Neben, C. L., Williams, H., Law, S., Zhou, A. Y., Wilemon, K. A., Ahmed, C. D., & Kindt, I. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.02.001 · Cited by 41
Self-citationTherapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia
Gelsinger, C., Steinhagen‐Thiessen, E., & Kassner, U. (2012) · Drugs · doi:10.2165/11635060-000000000-00000 · Cited by 38
Public health and precision medicine share a goal
Vaithinathan, A. G., & Asokan, V. (2016) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12239 · Cited by 37
Avis, H. J., Kusters, D. M., Vissers, M. N., Huijgen, R., Janssen, T. H., Wiegman, A., Kindt, I., Kastelein, J. J. P., Wijburg, F. A., & Hutten, B. A. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.12.037 · Cited by 35
Self-citationTargeted next-generation sequencing to diagnose disorders of HDL cholesterol
Sadananda, S. N., Foo, J. N., Toh, M. T., Cermakova, L., Trigueros‐Motos, L., Chan, T., Liany, H., Collins, J. A., Gerami, S., Singaraja, R. R., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p058891 · Cited by 36
Broekhuizen, K., van Poppel, M. N. M., Koppes, L. L. J., Kindt, I., Brug, J., & van Mechelen, W. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-181 · Cited by 36
Self-citationEfficacy and safety of mipomersen sodium (Kynamro)
Hovingh, K., Besseling, J., & Kastelein, J. J. P. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.793670 · Cited by 37
Self-citationPerez-Martinez, J. A., Schmeer, N., & Storz, J. (1986) · American Journal of Veterinary Research · doi:10.2460/ajvr.1986.47.07.1501 · Cited by 38
Goldberg, A. C., Robinson, J. G., Cromwell, W. C., Ross, J. L., & Ziajka, P. E. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.04.002 · Cited by 32
Farnier, M., Bruckert, É., Boileau, C., & Krempf, M. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.053 · Cited by 34
Langslet, G., & Ose, L. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.814851 · Cited by 32
Batais, M. A., Almigbal, T. H., Abdulhak, A. A. B., Altaradi, H. B., & AlHabib, K. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183494 · Cited by 31
A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia: Time to Widen the Scope?
Reeskamp, L. F., Hartgers, M. L., Peter, J., Dallinga‐Thie, G. M., Zuurbier, L. C., Defesche, J. C., Grefhorst, A., & Hovingh, G. K. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002385 · Cited by 30
Risk Factors for Cholecystectomy After Laparoscopic Roux-En-Y Gastric Bypass
Haal, S., Rondagh, D., Hutten, B. A., Acherman, Y. I. Z., van de Laar, A. W. J. M., Huijgen, R., Gerdes, V. E. A., & Voermans, R. P. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04166-y · Cited by 28
Self-citationKnowledge gaps in the management of familial hypercholesterolaemia. A UK based survey
Schofield, J. D., Kwok, S., France, M. W., Capps, N. E., Eatough, R., Yadav, R., Ray, K. K., & Soran, H. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.07.009 · Cited by 25
Severe familial hypercholesterolaemia: Current and future management
Farnier, M., & Bruckert, É. (2012) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2012.05.011 · Cited by 25
Banach, M., Lopez-Sendon, J. L., Averna, M. R., Cariou, B., Loy, M., Manvelian, G. Z., Batsu, I., Poulouin, Y., & Gaudet, D. (2021) · Archives of Medical Science · doi:10.5114/aoms/143476 · Cited by 25
Langslet, G., Bogsrud, M. P., Halvorsen, I., Fjeldstad, H. E., Retterstøl, K., Veierød, M. B., & Ose, L. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.08.008 · Cited by 27
Inheritance pattern of familial hypercholesterolemia and markers of cardiovascular risk
Kusters, D. M., Avis, H. J., Braamskamp, M. J. A. M., Huijgen, R., Wijburg, F. A., Kastelein, J. J. P., Wiegman, A., & Hutten, B. A. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m034538 · Cited by 25
Self-citationHartgers, M. L., Besseling, J., Stroes, E. S. G., Wittekoek, J., Rutten, J. H. W., Graaf, J. D., Visseren, F. L. J., Imholz, B. P. M., van Lennep, J. E. R., Huijgen, R., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.002 · Cited by 24
Self-citationCascade Screening in Familial Hypercholesterolemia: Advancing Forward
Santos, R. D., Frauches, T. S., & Chacra, A. P. M. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.31237 · Cited by 25
Faiz, F., Hooper, A. J., & BOCKXMEER, F. M. V. (2012) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.646942 · Cited by 24
Sommermeyer, D., Zou, D., Eder, D. N., Hedner, J. A., Ficker, J. H., Randerath, W. J., Priegnitz, C., Penzel, T., Fietze, I., Sanner, B. M., et al. (2013) · Journal of Hypertension · doi:10.1097/hjh.0000000000000039 · Cited by 27
Current Treatment of Familial Hypercholesterolaemia
Lambert, C. T., Sandesara, P. B., Isiadinso, I., Góngora, M. C., Eapen, D. J., Bhatia, N. K., Baer, J., & Sperling, L. S. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.2.76 · Cited by 23
A Review of PCSK9 Inhibitors and their Effects on Cardiovascular Diseases
Chen, B., Shi, X., Cui, Y., Hou, A., & Zhao, P. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190809094203 · Cited by 23
Dufour, R., Bergeron, J., Gaudet, D., Weiss, R., Hovingh, G. K., Qing, Z., Yang, F., Andisik, M. D., Torri, A., Pordy, R. C., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.046 · Cited by 24
Moriarty, P. M., Parhofer, K. G., Babirak, S. P., deGoma, E. M., Duell, P. B., Hohenstein, B., Ramlow, W., Simha, V., Steinhagen‐Thiessen, E., Thompson, P. D., et al. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.003 · Cited by 19
Auckle, R., Su, B., Li, H., Xu, S., Xie, M., Song, Y., Quddus, M. A., Xu, Y., Liu, B., & Che, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186815 · Cited by 23
Huijgen, R., Homsma, S. J. M., Hutten, B. A., Kindt, I., Vissers, M. N., Kastelein, J. J. P., & van Rijckevorsel, J. L. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2012.5 · Cited by 18
Self-citationDufour, R., Hovingh, G. K., Guyton, J. R., Langslet, G., Baccara‐Dinet, M. T., Din-Bell, C., Manvelian, G. Z., & Farnier, M. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.11.007 · Cited by 20
Paththinige, C. S., Rajapakse, J., Constantine, G., Sem, K. P., Singaraja, R. R., Jayasekara, R. W., & Dissanayake, V. H. W. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0763-z · Cited by 20
Wei, C.-Y., Quek, R. G. W., Villa, G., Gandra, S. R., Forbes, C. A., Ryder, S., Armstrong, N., Deshpande, S., Duffy, S., Kleijnen, J., et al. (2016) · PharmacoEconomics · doi:10.1007/s40273-016-0464-2 · Cited by 16
Consenso de expertos sobre la detección y el manejo clínico de la hipercolesterolemia familiar
Masana, L., Civeira, F., Pedro‐Botet, J., de Castro-Orós, I., Pocoví, M., Plana, N., Mateo‐Gállego, R., Jarauta, E., & Pedragosa, À. (2013) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2013.07.005 · Cited by 23
Ibrahim, S., Hartgers, M. L., Reeskamp, L. F., Zuurbier, L. C., Defesche, J. C., Kastelein, J. J. P., Stroes, E. S. G., Hovingh, G. K., & Huijgen, R. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117610 · Cited by 18
Self-citationGenotype-guided diagnosis in familial hypercholesterolemia: clinical management and concerns
Hopkins, P. N., & Lane, S. R. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000397 · Cited by 17
Young, J. M., Molyneux, S. L., Reinheimer, A. M., Florkowski, C. M., FRAMPTON, C. M. A., Scott, R. S., & George, P. M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.04.034 · Cited by 16
van Delden, X. M., Huijgen, R., Wolmarans, K. H., Brice, B. C., Barron, J. K., Blom, D. J., & Marais, A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.820 · Cited by 17
Self-citationD’Erasmo, L., Commodari, D., Costanzo, A. D., Minicocci, I., Polito, L., Ceci, F., Montali, A., Maranghi, M., & Arca, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.06.028 · Cited by 13
Patient Perspectives Regarding Genetic Testing for Familial Hypercholesterolemia
Marchand, M., Chen, V., Trinder, M., Cermakova, L., & Brunham, L. R. (2020) · CJC Open · doi:10.1016/j.cjco.2020.12.006 · Cited by 13
Korneva, V. A., Kuznetsova, Т. Y., & Julius, U. (2019) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2019.08.029 · Cited by 13
Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia
Besseling, J., Huijgen, R., Martin, S. S., Hutten, B. A., Kastelein, J. J. P., & Hovingh, G. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.033 · Cited by 10
Self-citationArca, M. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.09.001 · Cited by 12
Current novel-gene-finding strategy for autosomal-dominant hypercholesterolaemia needs refinement
Fouchier, S. W., Hutten, B. A., & Defesche, J. C. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102653 · Cited by 9
Self-citationБогачевская, С. А., & Николаевич, Б. А. (2017) · Social Aspects of Population Health · doi:10.21045/2071-5021-2017-53-1-1 · Cited by 10
Integrating genomics and precision health knowledge into practice: A guide for nurse practitioners
Walker, T. K., Ersig, A. L., Dwyer, A. A., Kronk, R. A., Snyder, C. T., Whitt, K. J., & Willis, V. (2024) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001050 · Cited by 10
Antisense oligonucleotides in the treatment of lipid disorders: pitfalls and promises.
Besseling, J., Hovingh, G. K., & Stroes, E. S. G. (2013) · PubMed · Cited by 8
Quality Assessment of the Genetic Test for Familial Hypercholesterolemia in The Netherlands
Kindt, I., Huijgen, R., Boekel, M., van der Gaag, K. J., Defesche, J. C., Kastelein, J. J. P., & de Knijff, P. (2013) · Cholesterol · doi:10.1155/2013/531658 · Cited by 8
Self-citationManagement of Hypercholesterolemia in Children
Braamskamp, M. J. A. M., Hutten, B. A., Wiegman, A., & Kastelein, J. J. P. (2014) · Pediatric Drugs · doi:10.1007/s40272-013-0060-2 · Cited by 12
Self-citationImproving the Monitoring and Care of Patients With Familial Hypercholesterolemia ∗
Hegele, R. A. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.01.041 · Cited by 8
Can we afford not to screen for FH?
Stoekenbroek, R. M., Kastelein, J. J. P., & Hovingh, G. K. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx197 · Cited by 8
Self-citationFaubert, S., Paquette, M., Baass, A. W., & Bernard, S. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110649 · Cited by 6
Familial hypercholesterolemia and young patients’ thoughts on own condition and treatment
Urke, E. B., Søbye, S. I., Ellingvåg, A., Langslet, G., Retterstøl, K., & Wandel, M. (2018) · Patient Education and Counseling · doi:10.1016/j.pec.2018.12.025 · Cited by 6
Burke, J. P., Simpson, R. J., Paoli, C. J., McPheeters, J., & Gandra, S. R. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.002 · Cited by 7
Li, B., Hao, P., Zhang, Y., Yin, R.-H., Kong, Q., Cai, X., Zhao, Z., Qi, J., Li, Y., Xiao, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10762 · Cited by 6
Metadata
- Authors
- Huijgen, R., Kindt, I., Verhoeven, S. B. J., Sijbrands, E. J. G., Vissers, M. N., Kastelein, J. J. P., & Hutten, B. A.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Erasmus MC (NL)
- Corresponding author
- Huijgen, Roeland
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-02-15
- Volume
- 5
- Issue
- 2
- Pages
- e9220
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2821409
- OpenAlex
- W2124402284
- Cited by
- 124
- References
- 30
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 3 · 2022: 4 · 2021: 1 · 2020: 11 · 2019: 6 · 2018: 11 · 2017: 8 · 2016: 14 · 2015: 11 · 2014: 9 · 2013: 14 · 2012: 16
- FWCI
- 13.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (acceptedVersion, other-oa)
- UvA-DARE (University of Amsterdam) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Pure Amsterdam UMC (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Rijksinstituut voor Volksgezondheid en Milieu
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- familial hypercholesterolemia, cholesterol-lowering therapy, LDL cholesterol targets, cardiovascular risk reduction, treatment goals
- MeSH terms
- Adolescent, Adult, Aged, Anticholesteremic Agents, Apolipoproteins B, Follow-Up Studies, Genetic Testing, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Middle Aged, Mutation, Netherlands, Surveys and Questionnaires, Receptors, LDL, Time Factors, Outcome Assessment, Health Care, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.